Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00392080 · ClinicalTrials.gov registry record · Phase 1
A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 340
- Enrollment target
NCT00392080 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 340 participants.
The verdict
NCT00392080, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 340 participants
- Enrollment target
Study Summary
CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.
Interventions
- DRUG placebo
- DRUG CJ-023,423
- DRUG naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 340 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00392080
The ClinicalTrials.gov registry entry for NCT00392080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 340 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00392080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00392080 about?
NCT00392080 is a clinical study titled "A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers". CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to pati...
What is the current status of trial NCT00392080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 340 participants. The study started on 2006-11. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00392080?
The interventions under investigation include: placebo (DRUG), CJ-023,423 (DRUG), naproxen (DRUG).
Who is sponsoring clinical trial NCT00392080?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.